Talon Therapeutics, Inc. Reports Third Quarter 2012 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and nine months ended September 30, 2012.
"FDA accelerated approval of Marqibo® (vinCRIStine sulfate LIPOSOME injection) is Talon's most important achievement to date," stated Steven R. Deitcher, M.D., President, Chief Executive Officer and Board Member of Talon. "The patient population Marqibo® will be serving is in need of new treatment options. We are in the process of evaluating a number of paths to commercialize Marqibo®, including a potential strategic transaction, licensing agreement, or a Talon launch."
"FDA accelerated approval of Marqibo® (vinCRIStine sulfate LIPOSOME injection) is Talon's most important achievement to date," stated Steven R. Deitcher, M.D., President, Chief Executive Officer and Board Member of Talon. "The patient population Marqibo® will be serving is in need of new treatment options. We are in the process of evaluating a number of paths to commercialize Marqibo®, including a potential strategic transaction, licensing agreement, or a Talon launch."